Oseltamivir oral suspension and capsules are bioequivalent for the active metabolite in healthy adult volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 47, Issue 8, 2009, Pages 539-548

  Lennon, Sian ^a   Barrett, J ^a   Kirtpartrick, C ^a   Rayner, C ^b  

^a ROCHE PRODUCTS LTD   (United Kingdom)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Bioequivalence; Influenza; Neuraminidase inhibitor; Oseltamivir; Pharmacokinetics

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; DRUG METABOLITE; OSELTAMIVIR;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL TRIAL; COLD SENSATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FATIGUE; FEMALE; FLATULENCE; GASTROINTESTINAL DISEASE; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SEDATION; SIDE EFFECT; SUSPENSION; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUNTEER; VOMITING;

ADULT; ANTIVIRAL AGENTS; AREA UNDER CURVE; CAPSULES; CROSS-OVER STUDIES; HUMANS; OSELTAMIVIR; SUSPENSIONS; THERAPEUTIC EQUIVALENCY;

EID: 70349122572     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.2379/CP200874     Document Type: Article

References (21)

1. Abrecht S, Harrington P, Iding H, Karpf M, Trussardi R, Wirz B, Zutter U. The synthetic development of the anti-influenza neuraminidase inhibitor oseltamivir phosphate (Tamiflu): a challenge for synthesis and process research. Chimia. 2004; 58: 621-629.
2. Bowles SK, Lee W, Simor AE, Vearncombe M, Loeb M, Tamblyn S, Fearon M, Li Y, McGeer A. Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999 - 2000. J Am Geriat Soc. 2002; 50: 608-616.
3. Dutkowski R, Thakrar B, Froehlich E, Suter P, Oo C, Ward P. Safety and pharmacology of oseltamivir in clinical use. Drug Saf. 2003; 26; 787-801.
4. F. Hoffmann-La Roche Ltd. Tamiflu® (oseltamivir). Prescribing Information, 2007a.
5. F. Hoffmann-La Roche Ltd. Tamiflu (oseltamivir). Summary of Product Characteristics, 2007b. Available at: http://www.rocheuk.com/ ProductDB/Documents/rx/spc/Tamiflu_Capsules_SPC.pdf. Last accessed June 6, 2007.
6. Hayden FG, Atmar RL, Schilling M, Johnson C, Poretz D, Paar D, Huson L, Ward P, Mills RG. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med. 1999; 341: 1336-1343.
7. Hayden FG, Belshe R, Villanueva C, Lanno R, Hughes C, Small I, Dutkowski R, Ward P, Carr J. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis. 2004; 189: 440-449.
8. He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet. 1999a; 37: 471-484.
9. He G, Massarella J, Schulz R, Woodruffe-Peacock C, Dorr A, Ward P, Brown A. The effect of food on the pharmacokinetics of the novel oral neuraminidase inhibitor Ro 64-0796/GS4104. The American Association of Pharmaceutical Scientists, Southeast Regional Meeting Durham, NC, USA; June 21, 1999b.
10. Hill G, Cihlar T, Oo C, Ho E, Prior K, Wiltshire H, Barrett J, Liu B, Ward P. The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion - correlation of in vivo and in vitro studies. Drug Metab Dis. 2002; 30: 13-19.
11. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med. 2003; 163: 1667-1724.
12. Kurowski M, Oo C, Wiltshire H, Barrett J. Oseltamivir distributes to influenza virus replication sites in the middle ear and sinuses. Clin Drug Investigation. 2004; 24: 49-53.
13. Mitamura K, Sugaya N, Nirasawa M, Shinjoh M, Takeuchi Y. Effectiveness of oseltamivir against influenza type A and type B infection in children. Kansenshogaku Zasshi. 2002; 76: 946-952.
14. Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH, Rhode A, Kinnersley N, Ward P. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet. 2000; 355: 1845-1850.
15. Oo C, Snell P, Barrett J, Dorr A, Liu B, Wilding I. Pharmacokinetics and delivery of the anti-influenza prodrug oseltamivir to the small intestine and colon using site-specific delivery capsules. Int J Pharm. 2003; 257: 297-299.
16. Parker R, Loewen N, Skowronski D. Experience with oseltamivir in the control of a nursing home influenza B outbreak. Can Commun Dis Rep. 2001; 27: 37-40.
17. Peters PH Jr, Gravenstein S, Norwood P, De Bock V, Van Couter A, Gibbens M, von Planta TA, Ward P. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc. 2001; 49: 1025-1031.
18. Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, Singh S, Kinnersley N, Ward P, Mills RG. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA. 2000; 283: 1016-1024.
19. Welliver R, Monto AS, Carewicz O, Schatteman E, Hassman M, Hedrick J, Jackson HC, Huson L, Ward P, Oxford JS. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA. 2001; 285: 748-754.
20. Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, Ipe D, Mills RG, Ward P. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J. 2001; 20: 127-133.
21. Wiltshire H, Wiltshire B, Citron A, Clarke T, Serpe C, Gray D, Herron W. Development of a high-performance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro 64-802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine. J Chromatogr. 2000; 745: 373-388.